Categories: BrainHealthcareNews

NeuroOne® to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

EDEN PRAIRIE, Minn., March 05, 2025 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced that it will participate in the upcoming Oppenheimer 35th Annual Healthcare Conference MedTech & Services Conference on Wednesday, March 19, 2025.

NeuroOne CEO Dave Rosa will host a virtual corporate presentation at 9:20 a.m. eastern time on Wednesday, March 19, 2025, followed by one-on-one meetings, which can be requested through Oppenheimer. To join live or view a replay of the webcast, please visit this link or the events page on NeuroOne’s investors relations website.

About NeuroOne
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit www.nmtc1.com.

IR Contact
Chris Donovan
MZ Group – MZ North America
NMTC@mzgroup.us
(914) 352-5853

Staff

Recent Posts

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

Appointment adds significant clinical and scientific expertise in the field of psychedelic-based therapiesNew York, New…

2 hours ago

Celebrating a Decade of Care: Aeroflow Urology Marks 10 Years of Supporting Those Afflicted by Incontinence Across the U.S.A.

Aeroflow Urology's 97% customer satisfaction rating is a testament to the company’s commitment to personalized…

2 hours ago

NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today’s Marketplace

EDEN PRAIRIE, Minn., March 18, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC)…

2 hours ago

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

-- Company taps first EU distributors, Comercial Medico Quirurigca, SA and Durgalab, as the first…

2 hours ago

Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI

SAN MATEO, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today…

2 hours ago